A10 is currently US based; however, A10 aims to go international utilizing US-based companies, with same standards, in various areas in emerging markets such as: China, India and Europe to increase overall diversity in clinical trials and create voluminous NDA’s – New Drug Application. Research will be performed in differing origins around the world in participants’ homeland. All research will be conducted in original environment to maximize accuracy and reliability of all collected data. Additionally, A10 will expand it onsite clinical care operations around the globe in partnership with our clients.
Entrepreneurs Shaping Public Policy: Hear A10 CEO Leah Brown at Ernst & Young Strategic Growth Forum November 2012